Overall, there was an average weight loss of 15% over 68 weeks
First, it involved a patient who already had neuropathy, raising the question of whether pre-existing nerve damage creates vulnerability to GLP-1-associated allodynia
Yes, and for people using multiple protocols, a unified tracking system is strongly preferable to separate logs for each peptide
The literature search and data extraction were performed by the authors
Many products sold as glp 1 patches, glp 1 weight loss patches, or appetite boosters are simply not the same thing
Consumer protection in this environment requires critical thinking skills: understanding mechanism versus marketing, recognizing when technically accurate claims create false impressions, and evaluating products based on evidence rather than pharmaceutical associations